PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Duksan Techopia's core semiconductor and OLED materials business is showing revenue growth, but consolidated losses have widened since 2023 as early-stage ramp-up costs at its battery-materials subsidiary and non-cash accounting charges weigh on the bottom line.
2025 revenue rose 12.4% year-over-year to KRW 112.1bn, but the operating loss widened 42.4% to KRW 43.0bn.
Revenue hit quarterly record highs of KRW 39.1bn and KRW 42.2bn in Q1 and Q2 2026, but the operating loss stayed roughly flat near KRW 10bn per quarter.
The core cash-cow HCDS semiconductor precursor benefits from AI datacenter-driven demand given its high share within Samsung Electronics' 3D NAND lines.
Subsidiary Deoksan Electera, which operates the Tennessee electrolyte plant, is a major driver of consolidated losses due to early-stage ramp-up costs.
The debt ratio jumped from 46.9% in 2022 to 507.4% in 2025, reflecting a sharp increase in financial leverage.
Founded in 2006 and listed on KOSDAQ in 2019, Duksan Techopia is a fine chemicals materials company operating semiconductor and display materials, secondary battery materials, and pharmaceutical intermediate businesses.
In semiconductors, its core product is hexachlorodisilane (HCDS), a precursor used in atomic layer deposition (ALD) processes, supplied mainly to Samsung Electronics' 3D NAND lines. In display, it supplies OLED emissive-layer organic material intermediates mainly to Samsung Display.
The secondary battery segment consists of electrolyte additives produced in-house and finished electrolyte products from subsidiary Deoksan Electera.
The pharmaceutical segment leverages peptide synthesis technology derived from OLED organic synthesis to supply intermediates for diabetes, MASH, and anti-cancer drugs to global CDMO clients.
According to brokerage reports, the 2025 revenue mix was approximately semiconductor 50%, OLED 35%, secondary battery 6%, pharma 5%, and other 4%, with the semiconductor and OLED segments together accounting for about 85% of sales.
The company supplies HCDS to Samsung Electronics' 3D NAND process and holds a 60-70% market share.
The battery segment is divided between its own electrolyte additive business and subsidiary Deoksan Electera's finished electrolyte products, with this year marking the start of full-scale operation at Deoksan Electera's Tennessee plant (100,000-ton capacity, roughly KRW 1 trillion in revenue potential).
Key customers include Samsung Electronics, Samsung Display, SK On, and multiple global pharmaceutical companies.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩29B | -₩8.7B | −30.1% |
| 2025Q3 | ₩30.1B | -₩14.9B | −49.4% |
| 2025Q4 | ₩28.8B | -₩9.7B | −33.7% |
| 2026Q1 | ₩39.1B | -₩10.4B | −26.5% |
| 2026Q2 | ₩42.2B | -₩10.6B | −25.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩111B | ₩9.3B | ₩16.1B | 8.3% | 8.5% | 46.9% |
| 2023 | ₩94.1B | -₩6.2B | -₩7.4B | −6.6% | −4.2% | 179.1% |
| 2024 | ₩99.7B | -₩30.2B | -₩53.1B | −30.3% | −26.8% | 222.2% |
| 2025 | ₩112.1B | -₩43B | -₩76.7B | −38.4% | −66.6% | 507.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated 2025 revenue was KRW 112.08bn, up 12.4% from KRW 99.69bn in 2024, but the operating loss widened 42.4% to KRW 43.03bn from KRW 30.22bn. Net loss attributable to owners also expanded sharply to KRW 76.7bn from KRW 53.1bn a year earlier.
The company disclosed that depreciation and ramp-up cost increases from the full-scale operation of Deoksan Electera's North America plant contributed to the widened operating loss, while revenue growth was driven by full-scale shipments in the new electrolyte and pharmaceutical intermediate businesses.
The widened net loss was also affected by the fact that roughly KRW 57.4bn in additional derivative valuation expense related to redeemable convertible preferred stock (RCPS) was recognized due to a rise in Deoksan Electera's enterprise value, a non-cash accounting item with no actual cash outflow.
On a quarterly basis, Q3 2025 revenue was KRW 30.05bn with an operating loss of KRW 14.86bn, while Q4 2025 revenue was KRW 28.81bn with a smaller operating loss of KRW 9.72bn, yet net loss attributable to owners reached KRW 47.48bn, suggesting a large one-time charge in that quarter.
Into 2026, Q1 revenue was KRW 39.14bn with an operating loss of KRW 10.38bn, and Q2 revenue reached KRW 42.18bn with an operating loss of KRW 10.56bn, meaning revenue set consecutive quarterly records but the operating loss did not meaningfully narrow.
The trailing four-quarter (Q3 2025-Q2 2026) net loss attributable to owners totaled roughly KRW 82.7bn.
This contrasts with 2022, when the company posted revenue of KRW 111.0bn alongside an operating profit of KRW 9.26bn and net profit of KRW 16.06bn, underscoring that the past three years of losses reflect structural cost burdens tied to new business investment.
The semiconductor materials segment is closely tied to the recovery in NAND flash demand driven by expanding AI datacenter investment. Increased SSD and NAND demand from AI datacenter expansion, combined with more frequent ALD process steps from process node advancement, is structurally increasing HCDS consumption.
The OLED segment has shown a gradual recovery in line with expanding OLED adoption in smartphones and tablets, with revenue increasing year-over-year.
The battery electrolyte market is shaped by ESS demand and localization incentives under the US Inflation Reduction Act (IRA), and amid a clear de-China trend driven by IRA implementation, the completed 100,000-ton-capacity electrolyte plant in Tennessee is regarded as the largest single plant in North America.
However, the battery segment remains in an early ramp-up phase where cost burdens still outweigh profit contribution. The peptide CDMO market is drawing attention amid growing global GLP-1 obesity drug demand, though the company's related revenue share remains small at around 5%.
Competitively, the semiconductor precursor business maintains high customer concentration and entry barriers, while the battery electrolyte market involves competition among multiple domestic and overseas players, making new customer acquisition a key variable to watch.
Brokerages view 2026 as a turning point where the core business recovery and new venture growth converge.
In an April 16, 2026 report, SK Securities forecast that the company's battery segment revenue would surge from KRW 6.3bn in 2025 to KRW 127.1bn in 2026 and KRW 263.2bn in 2027, with ESS revenue mix rising from 40% in 2025 to over 70% in 2026, and that profitability would turn positive in 2026 before profit generation becomes substantial from 2027.
The same report stated on the pharmaceutical segment that following completion of a second plant in Q4 and K-GMP certification in the first half of 2027, the company would enter full-scale production, with combined capacity across both plants estimated at about KRW 160bn, reaching breakeven in 2026 and generating profit from 2027.
Leading Investment & Securities forecast in an April 19, 2026 report that the company's expected 2026 results would be revenue of KRW 236.2bn (up 110.7% year-over-year) and operating profit of KRW 13.7bn (a swing to profit from a loss).
However, while actual Q1-Q2 2026 results confirmed revenue growth, the operating loss remained near KRW 10bn per quarter, meaning the actual timing of a profit turnaround still needs to be confirmed through upcoming quarterly results.
The semiconductor segment is expected to see stable growth from AI-driven NAND demand, while the pace of utilization ramp-up at the North American battery plant will be a key variable for earnings improvement.
Duksan Techopia has posted consecutive net losses in recent years, making a conventional price-to-earnings ratio difficult to calculate—a pattern often seen in materials companies in an investment-heavy growth phase.
The stock trades at a level above net asset value per share, which can be interpreted as reflecting both the cash-generating capacity of the core semiconductor and OLED business and growth expectations for the battery and biopharma new ventures.
With no recent dividend payment history, valuation comparisons based on dividend yield carry limited relevance.
The sharp rise in the debt ratio from 46.9% in 2022 to 507.4% in 2025 reflects a shift in the balance sheet structure driven by new business investment, and this financial leverage trend warrants attention alongside the pace of any earnings recovery.
Ultimately, the current share price level can be seen as embedding a substantial degree of market expectation around when and how quickly a swing from losses to profit might occur.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The core cash-cow HCDS precursor maintains an overwhelming market share within Samsung Electronics' 3D NAND lines. Expanding AI datacenter investment is driving increased SSD and NAND demand along with more ALD process steps, structurally boosting HCDS consumption.
This semiconductor materials demand growth underpins the consecutive quarterly revenue records set in Q1-Q2 2026.
The North American electrolyte plant in Tennessee, operated by subsidiary Deoksan Electera, is considered the largest single plant of its kind in North America. With IRA-driven localization incentives and ESS demand recovery converging, there is potential for substantial revenue expansion as utilization rises.
Analysts project this business could swing to profit in 2026, with profit contribution becoming more substantial from 2027.
Leveraging peptide synthesis capabilities derived from OLED organic synthesis technology, the company supplies pharmaceutical intermediates for diabetes, MASH, and anti-cancer drugs to global CDMO clients.
With a second plant completion scheduled for Q4 2026 and K-GMP certification targeted for the first half of 2027, this could contribute to portfolio diversification over the medium to long term. It is viewed as a long-term growth option amid growth in the global obesity drug market.
Operating losses have widened every year, from KRW 6.2bn in 2023 to KRW 30.2bn in 2024 and KRW 43.0bn in 2025. Even in Q1-Q2 2026, while revenue grew, the operating loss did not meaningfully narrow from the roughly KRW 10bn per quarter level.
The possibility that cost burdens from new business investment persist longer than expected cannot be ruled out.
Depreciation and ramp-up costs at the North American plant have been cited as the primary driver of the widened consolidated operating loss.
Due to early-stage operating cost burdens, subsidiary Deoksan Electera, which handles the electrolyte business, recorded a loss of roughly KRW 15bn, contributing to continued consolidated losses. If the utilization ramp-up is delayed beyond expectations, the loss-making phase could extend further.
The debt ratio rose sharply from 46.9% in 2022 to 507.4% in 2025. Over the same period, total equity fell from KRW 203.3bn in 2022 to KRW 106.5bn in 2025.
The rapid deterioration in the balance sheet structure, driven by a combination of new business investment and accumulated losses, could lead to a need for additional financing going forward.
A significant portion of semiconductor and OLED revenue is concentrated with Samsung Electronics and Samsung Display, meaning changes in these customers' investment plans or supply chain strategies could directly affect results. Customer diversification efforts are underway but remain at an early stage.
The battery electrolyte business's performance is heavily dependent on the pace of securing new contracts with global automakers and cell manufacturers. If expected customer acquisitions are delayed or ESS/EV demand recovery is slower than anticipated, the timing of utilization improvement could be pushed back.
Derivative valuation gains or losses related to Deoksan Electera's redeemable convertible preferred stock (RCPS) can swing significantly each quarter depending on changes in the subsidiary's enterprise value.
In 2025, an additional derivative valuation expense of roughly KRW 57.4bn was recognized due to a rise in Deoksan Electera's enterprise value, a non-cash accounting item with no actual cash outflow, but it complicates interpretation of net income figures.
The Q3 2026 quarterly report is due. It will be important to confirm whether revenue growth continues and whether the operating loss actually narrows.
Progress on the completion of the second pharmaceutical intermediate plant should be checked. Whether the K-GMP certification process scheduled for the first half of 2027 begins on time is also worth watching.
The size of RCPS derivative valuation gains or losses related to Deoksan Electera needs to be re-checked. Volatility in this non-cash item can significantly sway net income figures.
Disclosures on the pace of utilization increase at the Tennessee electrolyte plant and new customer acquisitions among global automakers and cell manufacturers should be tracked.
Duksan Techopia is at a transition point where revenue growth in its core semiconductor and OLED business coincides with ongoing investment costs in new battery and biopharma ventures.
Operating losses widened for three consecutive years through 2025, and while revenue set consecutive quarterly records in H1 2026, the operating loss did not narrow meaningfully.
Brokerages project earnings improvement in 2026-2027 based on rising utilization at Deoksan Electera's North American plant and the launch of a second pharmaceutical plant, but these remain unrealized estimates.
A sharp rise in the debt ratio and volatility from RCPS-related non-cash items complicate interpretation of financial metrics. Whether the operating loss actually narrows in upcoming quarters and whether the battery subsidiary's utilization rises as planned will be the key points to watch.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.